NHS approves £1.65m gene therapy for sickle cell disease, offering a potential cure. A milestone for patients, especially in ...

A new gene editing treatment has been approved for use in the NHS, which will help treat sickle cell disease patients ...

People in England to benefit from groundbreaking one-off gene therapy for severe sickle cell disease approved by NICE ...

Experts hailed exciting news for some people with sickle cell disease in England as the health watchdog decided to grant ...

We can do better. We can build a system that provides coordinated high-quality care to every patient who needs it.

NHS patients with sickle cell disease will be able to benefit from a groundbreaking gene-editing treatment that offers the prospect of a cure for the condition. The one-off gene therapy, known as ...

Vertex Pharma's £1.65 million ($2.05 million) gene-editing therapy for sickle cell disease (SCD), Casgevy, has been given the ...

Base editing utilizes enzymes to modify single amino acids at the most foundational unit of DNA, called a base.

Around 1,700 people could be eligible for the one-time treatment, which is seen as a less risky alternative to a donor stem ...

Britain's National Health Service (NHS) will provide a cutting-edge gene therapy that aims to cure sickle cell disease, the ...

The National Institute for Health and Care Excellence (NICE) has approved Vertex Pharmaceuticals’ Casgevy (exagamglogene ...

A gene-editing therapy for sickle cell disease, with a price tag of £1.65m, is to be offered to patients on the NHS in ...